Cinco mentes
Una cartera
Cero ruido

Definición: Clase de fármacos (agonistas receptor GLP-1) que trasciende diabetes/obesidad para reescribir economía cardiovascular, dispositivos médicos, retail alimentario y manufactura farmacéutica simultáneamente. Superciclo confirmado: no es una droga, es un healthcare system stress test.

---

Magnitud del Superciclo (Emergen Research Q1 2026)

| Métrica | Valor | Significado | |---------|-------|-------------| | Market size 2025 | $26.8B | Base real | | Market size 2035 | $168B | Proyección estructural | | Revenue CAGR 2025-35 | 22.4% | Superciclo confirmado | | Población elegible | 890M adultos obesos | Global, no solo US/EU | | Ecosystem value 2025-35 | $1.2T cumulative | Healthcare system impact | | US users 2025 | ~10M | 6M 2024, 5M 2023 | | US users 2030 | 25-30M | JPMorgan forecast | | Global users 2030 | ~100M | Extrapolación |

---

Duopolio actual: Lilly vs Novo (Q4 2025)

| Empresa | Portfolio | Revenue | Growth | Posición | |---------|-----------|---------|--------|----------| | Eli Lilly | Mounjaro (diabetes), Zepbound (obesidad) | $19.3B Q4 2025 | +43% YoY | Líder aceleración | | | Foundayo (oral orforglipron) | FDA approved Apr 2026 | Triple agonista pipeline | | | Retatrutide (triple agonist) | Phase 3 | 2030+ | | Novo Nordisk | Ozempic (diabetes), Wegovy (obesidad) | DKK 201.8B ($29.3B) 2024 | +26% CER 2024 | Líder estable | | | Rybelsus (oral semaglutide) | DKK 65.1B ($9.5B) 2024 | +57% CER | Oral advantage | | | CagriSema (semaglutide+cagrilintide) | Phase 3 | 2027+ |

Desacoplamiento 2025: Lilly tirzepatide Q4 $11.6B vs Novo Ozempic DKK 31.8B (+1% CER) → Lilly lidera crecimiento.

---

Catalizadores estructurales 2026-2030

1. Oral GLP-1s: Game changer — manufacturabilidad vs inyectables

| Producto | Tipo | Estado | Impacto | |----------|------|--------|---------| | Foundayo (Lilly) | Oral small molecule | FDA approved Apr 2026 | No fill-finish constraint | | | Orforglipron | 27.3 lb weight loss (Phase 3) | Daily dosing, no food/water | | Wegovy oral (Novo) | Oral semaglutide | FDA approved Dec 2025 | 16.6% weight loss at 64 weeks | | | Rybelsus oral | Existing | Daily, but requires fasting | | Amycretin (Novo) | GLP-1/amylin oral | Phase 1 | 13% weight loss in 12 weeks |

Manufacturabilidad: Oral = tablet lines vs injectables = cold chain, sterile fill-finish → escala masiva.

2. Manufacturing capacity: $50B+ capex — API bottleneck

| Empresa | Investment | Timeline | Focus | |---------|-----------|----------|-------| | Eli Lilly | $27B (2025) | 2027-2030 | API + injectables + oral | | | Lebanon, IN | 2027 | Largest API site US history | | | Goochland, VA | 2028 | Integrated API + drug-product | | | Germany (Lonza) | 2028 | GLP-1 API facility | | Novo Nordisk | $9B (2025) | 2027-2029 | Fill-finish + API | | | Clayton, NC #2 | 2027-2029 | 1.4M sq ft, 1,000 jobs | | | Athlone, Ireland | 2027-2028 | Oral GLP-1 capacity | | | Kalundborg, Denmark | 2024 | API expansion |

Bottleneck actual: Fill-finish capacity → 35% demand > supply through 2027 (Emergen Research).

3. Label expansions: Beyond obesidad → comorbidades

| Indicación | Empresa | Estado | Impacto | |------------|---------|--------|---------| | HFpEF (heart failure) | Novo semaglutide | FDA review Q1 2026 | 3.5M US patients | | Sleep apnea | Lilly tirzepatide | Phase 3 | Sleep quality improvement | | NASH (liver disease) | Boehringer survodutide | Phase 3 | Metabolic steatohepatitis | | Kidney disease | Multiple | Phase 2-3 | Renal protection | | Neurodegenerative | Multiple | Preclinical | Alzheimer's, Parkinson's |

Impacto: Cada nueva indicación duplica el mercado addressable.

4. Payer coverage: IRA pricing access inflection

| Payer Type | Coverage Status | Pricing Impact | |------------|----------------|---------------| | Medicare Part D | Ozempic/Wegovy in Round 2 | $274/month vs $959 list (Jan 2027) | | | Tirzepatide not in Round 2 | Protected until 2029+ | | Commercial insurance | ~25% cover obesidad | Near-universal for diabetes | | Medicaid | Limited coverage | Expansion ongoing | | Self-pay | $349-$1,349/month | Cash market growing |

Timeline crítico: Jan 2027 IRA pricing takes effect → access expansion.

---

Pipeline: Next wave 2026-2030

Triple agonists (2027-2030)

• Retatrutide (Lilly): Triple GLP-1/GIP/glucagon → Phase 3 obesidad
• CagriSema (Novo): Semaglutide + cagrilintide → Phase 3
• Survodutide (Boehringer): Glucagon + GLP-1 → NASH + obesidad

Oral formulations (2026-2027)

• Foundayo (Lilly): Approved Apr 2026 → oral small molecule
• Wegovy oral (Novo): Approved Dec 2025 → oral semaglutide
• Amycretin (Novo): GLP-1 + amylin → Phase 1

Combination therapies (2028-2030)

• Multiple GLP-1 combinations → enhanced efficacy, tolerability
• Fixed-dose combinations → adherence improvement

Biosimilar inflection (2031-2033)

• Semaglutide biosimilars: FDA guidance Mar 2025 → first by 2033
• Price compression: 70-80% below brand → access expansion

---

Impacto sistema: $1.2T ecosystem value

Healthcare system impact

| Sector | Impact | Timeline | |--------|--------|----------| | Cardiovascular procedures | Reduced events | 2027-2030 | | Diabetes management | Lower HbA1c, complications | 2026+ | | Kidney disease | Slowed progression | 2028+ | | Healthcare costs | $30-55B annual reduction | 2030-2034 |

Food & beverage impact (JPMorgan 2026)

• US households with GLP-1 users: -12% snack food, -9% sugary beverages, +7% protein
• Industry revenue reduction: $30-55B by 2030-2034
• Consumer behavior: 21% fewer calories, 31% less grocery spending

Food industry response

• Nestlé: Dedicated GLP-1 nutrition platform (Oct 2024)
• Conagra: 40 SKUs reformulated for reduced portions + protein
• General Mills: Protein-focused product development

---

Jugadores principales — Posicionamiento 2026

| Empresa | Modelo | Posición | Thesis Status | |---------|--------|----------|---------------| | Eli Lilly | GLP-1 platform (tirzepatide + orforglipron) | BUY | Triple agonist, oral advantage, IRA protection until 2029 | | Novo Nordisk | GLP-1 legacy (semaglutide + oral) | WATCHLIST | Strong brand but IRA exposure 2027, CagriSema execution risk | | Amgen | MariTide (once monthly dual action) | WATCHLIST | Long-acting formulation, obesity entry | | Boehringer Ingelheim | Survodutide (glucagon + GLP-1) | WATCHLIST | NASH + obesity, metabolic focus | | AstraZeneca | Partnership with CSPC China | WATCHLIST | China market access, innovation sourcing | | Merck | Keytruda (oncology crossover) | WATCHLIST | Cardio-metabolic potential | | Pfizer | Metsera acquisition (2025) | WATCHLIST | Obesity portfolio expansion | | Sanofi | Multiple GLP-1 partnerships | WATCHLIST | Late entry, potential upside |

---

KPIs para valorar empresa GLP-1 (actualizado)

• Portfolio diversification: Multiple GLP-1 assets across routes/oral/injectable
• Manufacturing capacity: API vs fill-finish, geographic diversification
• Payer coverage: Commercial/Medicaid/Medicare penetration, IRA exposure timing
• Pipeline depth: Next-gen agonists, oral formulations, combination therapies
• Real-world evidence: Persistence rates, cardiovascular outcomes, system cost savings
• Global reach: US/EU/Japan/China market access, emerging market penetration
• Biosimilar strategy: Patent cliff timing, biosimilar pipeline development
• Manufacturing economics: Cost per dose, scale advantages, cold chain requirements

---

Banderas rojas sector (actualizado)

• IRA pricing compression: Semaglutide exposed Jan 2027 → $274/month vs $959 list
• Manufacturing overcapacity: Fill-finish capacity at risk if oral wins share faster
• Persistence rates: Current 30-35% → needs to stabilize >40% for system value
• Competition intensification: Multiple entrants → pricing pressure, differentiation challenge
• Oral adoption: Adherence challenges with daily dosing vs weekly injections
• Global access: Pricing in emerging markets, supply chain constraints
• Regulatory pathway: Biosimilar guidance established but execution uncertain

---

Las dos caras hoy (sep-2026)

Alcista:

• Superciclo confirmado: $168B 2035, CAGR 22.4%, 890M eligible population
• Lilly lidera crecimiento: Tirzepatide $11.6B Q4 2025, Foundayo oral advantage, IRA protection until 2029
• Oral GLP-1s: Foundayo approved Apr 2026, Wegovy oral Dec 2025 → manufacturabilidad revolution
• Manufacturing $50B+ capex: API + fill-finish expansion, supply constraint through 2027
• Ecosystem value $1.2T: Healthcare system impact, food industry transformation
• Cartera Carlos 0% farma = hueco diversificación factorial real (innovación defensiva, healthcare secular)

Bajista:

• IRA pricing compression: Novo semaglutide exposed Jan 2027 → $274/month vs $959 list
• Manufacturing risk: Fill-finish capacity at risk if oral wins share faster than expected
• Persistence rates: Current 30-35% → needs >40% for sustainable system value
• Competition wave: Multiple entrants → pricing pressure, differentiation challenge
• Valoraciones: Multiples exigentes para líderes vs historia farmacéutica

---

Voces del cerebro y encaje con Carlos

• Posiciones: ninguna — hueco identificado cio-2026-07-16 (Inés Torres, estrategia sectorial).
• Candidatas cribadas tesis completa: eli-lilly (BUY, triple agonist, oral advantage, IRA protection).
• Nuevas watchlist entries: novo-nordisk (WATCHLIST, strong brand but IRA exposure), amgen (WATCHLIST, once monthly), boehringer ingelheim (WATCHLIST, NASH focus).
• Conceptos: foso-economico (manufacturing moat, API synthesis expertise) · ciclo de innovacion (oral vs injectable transformation) · valoracion-ciclicas-y-beneficios-negativos (no pagar de más por narrativa) · carteras-concentradas (diversificación factorial).
• Voces afines: philip-fisher (portfolio diversification) · howard-marks (innovation cycles, not linear extrapolation) · warren-buffett (moats en manufacturing y pipeline).

---

Nota de evolución 2026-09-03 (elisa-fernandez)

Concepto sintetizado tras investigación masiva GLP-1. Superciclo confirmado: $168B 2035, CAGR 22.4%, 890M eligible global population. Lilly lidera con tirzepatide + orforglipron oral + triple agonist pipeline. Novo tiene IRA exposure 2027. Oral GLP-1s = manufacturabilidad transformada. Manufacturing $50B+ capex = supply constraint through 2027. Ecosystem value $1.2T = healthcare + food industry transformation.

---

Ver también

— dato privado retirado —